Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
May 17, 2024

Sol-Gel, Beimei sign deal for TWYNEO commercialisation

Sol-Gel Technologies has entered into an asset purchase agreement with Shenzhen Beimei Pharmaceutical, granting the latter exclusive rights to commercialise Sol-Gel’s dermatology product TWYNEO in mainland China, Taiwan, Hong Kong, Macau, and Israel.  

Continue
The agreement will allow Beimei to manage the commercialisation, which includes licenses rights and purchases, of TWYNEO in the specified territories. Credit: Kjerstin_Michaela/Pixabay.
May 16, 2024

Scorpius announces validation of microbial facilities

The latest milestone means that the company’s microbial facilities are now qualified for the production of cGMP microbial biologic drugs. Credit: Testalize.me on Unsplash.
May 15, 2024

FogPharma and ARTBIO collaborate to co-develop new cancer therapies

The two partners will contribute equally to the research, development, and commercialisation phases of the collaboration. Credit: Tatiana from Pixabay.

Contracts

December 14, 2022

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Micrograph of psoriasis vulgaris. Credit: Jenny Giang, Marc A. J. Seelen, Martijn B. A. van Doorn, Robert Rissmann,Errol P. Prens and Jeffrey Damman/ commons.wikimedia.org.

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Harbour BioMed, Moderna partner on immunotherapies development

Kite, Refuge sign license deal for gene expression platform for blood cancers

Deals

Deals April 18, 2024

Biocon signs licensing and supply deal for diabetes drug in Brazil

Pharmaceutical Business Review

Q32 Bio concludes merger deal with Homology Medicines

Zuellig Pharma acquires Cialis and Alimta brands from Lilly

Kindeva Drug Delivery acquires Summit Biosciences

Popular

  1. PharmaLogic launches new radiopharmaceutical facility in New York, US
  2. Aardvark Therapeutics secures $85m in Series C funding round
  3. IMA Life to build new pharma freeze-drying equipment production site
  4. ImmunoACT and Caring Cross sign TriCAR-T cell therapy development deal
  5. OverT Bio secures $16m in seed funding for cell therapy development

PRESS RELEASES

Gerresheimer Performance Levels Simplify Choice of Optimum Solution
Gerresheimer Performance Levels Simplify Choice of Optimum Solution
Sofgen Pharmaceuticals to Exhibit at CPhI North America 2024
Sofgen Pharmaceuticals to Exhibit at CPhI North America 2024
Molnar Institute at Analytica 2024 – 9-12 April in Munich, Germany
Molnar Institute at Analytica 2024 – 9-12 April in Munich, Germany
Gerresheimer Decisively Continues on Profitable Growth Course in Financial Year 2023
Gerresheimer Decisively Continues on Profitable Growth Course in Financial Year 2023
Butterworth at Making Pharmaceuticals 2024 – 23-24 April in Coventry, UK
Butterworth at Making Pharmaceuticals 2024 – 23-24 April in Coventry, UK

Suppliers

Whitepapers

Wound Care – Selecting the Right Antiseptic for Your Formulation
Wound Care – Selecting the Right Antiseptic for Your Formulation
Topicals – Selecting the Right Antiseptic for Your Formulation
Topicals – Selecting the Right Antiseptic for Your Formulation
Oral Formulations – Selecting the Right Antiseptic for Your Formulation
Oral Formulations – Selecting the Right Antiseptic for Your Formulation